Assessment of the Therapeutic Utility of hMG-HP

Inclusion Criteria: * Women aged 18-38 years * Body mass index (BMI) between 18 and 30 * Women classified as normogonadotrophin patients. Not more than 3 previous cycles of ART (assisted reproductive technology) * Testosterona, FSH (follicle-stimulating hormone) LH (luteinizing hormone) and Prolactin serum levels during the early folicular phase (days 2-4 of the cycle) within the laboratory normal range * No administration of clomiphen citrate or gonadotropins during the month prior to the start of the study Exclusion Criteria: * Failure in previous cycles of assisted reproduction IVF/ICSI (in-vitro fertilisation/intracytoplasmic sperm injection) * Seminal samples not apt for IVF-ICSI (according to the criteria of each center). Evidence of significant bacterial infection in the seminogram of the couple in the preceding 6 months * Data suggestive of possible ovarian failure * Antecedents of severe ovarian hyperstimulation syndrome (OHSS) * Important systemic disease * Pregnancy or contraindication to pregnancy